Cartesian Therapeutics
RNAC
106 hedge funds and large institutions have $186M invested in Cartesian Therapeutics in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 35 increasing their positions, 33 reducing their positions, and 14 closing their positions.
732% more call options, than puts
Call options by funds: $815K | Put options by funds: $98K
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
3% more funds holding
Funds holding: 103 → 106 (+3)
6% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 33
0.13% more ownership
Funds ownership: 1.5% → 1.63% (+0.13%)
14% less capital invested
Capital invested by funds: $217M → $186M (-$31.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$7.14M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$5.03M |
| 3 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$4.34M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$3.95M |
| 5 |
Morgan Stanley
New York
|
+$2.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$9.75M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$4.26M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$2.69M |
| 4 |
JP Morgan Chase
New York
|
-$1.92M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$1.71M |
RNAC Hedge Fund Activity: Q4 2021 in Review
106 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q4 2021, worth a combined $186M — down 14% from $217M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new RNAC positions and 14 closed out — a net gain of 4 holders — while 35 added to existing stakes and 33 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $7.14M. The largest seller was State Street, cutting an estimated $9.75M.
- 106 institutional investors held Cartesian Therapeutics (RNAC) as of Q4 2021, up from 103 in Q3 2021.
- Funds reported $186M of Cartesian Therapeutics stock for Q4 2021, down 14% quarter-over-quarter.
- 18 funds opened new Cartesian Therapeutics positions in Q4 2021 and 14 closed out, a net change of +4 holders.
- The largest Cartesian Therapeutics buyer in Q4 2021 was Marshall Wace, an estimated $7.14M added.
- The largest Cartesian Therapeutics seller in Q4 2021 was State Street, an estimated $9.75M sold.
Based on aggregated 13F filings for Q4 2021.